Targeting Mutated K-ras in Pancreatic Adenocarcinoma Using an Adjuvant Vaccine

Abstract

K-ras vaccination for patients with resectable pancreatic adenocarcinoma proved to be safe and tolerable with however no elicitable immunogenicity and unproven efficacy. Future development of adjuvant vaccine therapies should use more immunogenic vaccines.